Moussa Seck1,3, Alioune Badara Senghor2, Mossane Loum3, Sokhna Aissatou Touré3, Blaise Félix Faye1,3, Alioune Badara Diallo3, Mohamed Keita3, Seydi Elimane Bousso3, Sérigne Mourtalla Guèye2,3, Macoura Gadji1,2, Abibatou Sall1,4, Awa Oumar Touré1,5 and Saliou Diop1,2,3.
1 Department of Hematology, Cheikh Anta Diop University, Dakar, Senegal.
2 National Blood Transfusion Center, Dakar, Senegal.
3 Clinical Hematology Department, CNTS, Dakar, Senegal.
4 Hematology Laboratory, Dalal Jamm Hospital, Dakar, Senegal.
5 Hematology Laboratory, Aristide Le Dantec Hospital, Dakar, Senegal.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Context and Objectives:
Blood transfusions (BT) remain a mainstay of therapy for patients with
sickle cell disease (SCD) but pose significant clinical challenges. We
aim to assess infectious markers, red cell alloimmunization, and iron
overload secondary to BT in SCD patients.
Materials and Methods
|Table 1. Baseline characteristics of SCD-transfused and SCD non-transfused patients.
1. SCD-Transfused patients and number of RBCS received.
|Table 2. Frequency and specificity of anti-erythrocyte alloantibodies..
|Figure 2. Correlation between RBCS units received and ferritin levels.
|Table 3. Risk factors associated with infectious markers, RCA and iron overload.